Lymphangiomyomatosis in Bourneville’s Tuberous Sclerosis

El ismaili A¹, Serraj M², Amara B² and MC Benjelloun²

¹Faculty of Medicine and Pharmacy, University Sidi Mohamed Ben Abdellah, Fes, Morocco
²Department of pneumology, University Hospital Hassan II, Fes, Morocco

Corresponding author: El ismaili A, Faculty of Medicine and Pharmacy, University Sidi Mohamed Ben Abdellah, Fes, Morocco, Tel: 0693519922, E-mail: asmaeelismaili88@gmail.com

Citation: MEI ismaili A, Serraj M, Amara B, MC Benjelloun (2020) Lymphangiomyomatosis in Bourneville’s Tuberous Sclerosis. J Pulmonol Respir Disord 1: 103

Abstract
Lymphangiomyomatosis is a rare disease characterized by a proliferation of abnormal smooth muscle cells responsible for infiltration with destruction of tissue architecture and genesis of cystic lung and lymphatic lesions.
In addition to lung damage, Bourneville’s tuberous sclerosis (BTS) affects also the skin, brain, retina, kidneys and, less frequently, the heart and bone. We report the case of a young patient with bilateral pneumothorax revealing pulmonary lymphangiomyomatosis in the context of BTS.

Keywords: Bilateral Pneumothorax; Lymphangiomyomatosis; Bourneville’s Tuberous Sclerosis

Introduction
There is a genetic relationship with BTS and lymphangiomyomatosis, including the participation of the TSC2 gene, that’s why clinicians need to be conscious of the association and to make a STB assessment in the face of any suspicion of lymphangiomyomatosis (namely bilateral pneumothorax). Lymphangiomyomatosis is a young woman's disease, often revealed by recurrent pneumothorax, with or without exertional dyspnea. The analysis of molecular mechanisms during BTS and lymphangiomyomatosis and the demonstration of migratory properties of smooth muscle cells reveal specific antiproliferative therapeutic prospects.

Observation/ Results
She is a patient aged 25 yo, mentally retarded, followed for an undocumented kidney problem for the last 4 years.
Since 4 months, she reports dyspnea of effort with aggravation of the bilateral lumbar pain. the symptomatology increased one month ago by a dyspnea of rest with a dry cough without chest pain or hemoptysis, which prompted her to go to the emergency, the clinical examination found a polypneic patient at 32 c/ min sao2 at 79%, intercostal draught with a bilateral air epilepticus syndrome. A chest X-ray was taken, showing a bilateral pneumothorax of great abundance on the right and a partial pneumothorax on the left.

Figure 1: CT scan showing a bilateral cystic pulmonary lesion and a right pneumothorax in the context of tuberous bourneville sclerosis
The diagnosis of Bourneville’s tubular sclerosis was retained. In search of other abnormalities, a cardiology consult with cardiac echography ruled out a heart condition as well as an ophthalmological examination. In addition to the chest abnormalities, the scan showed subependymal cerebral nodules (Figure 2) and renal mass on both sides (angiomyolipoma) (Figure 3).

The patient was drained on both sides with good evolution. Elsewhere, skin examination found fibrous plaques on the forehead, papular lesions on both cheeks and on the wings of the nose, acromic plaques on the external surface of the left thigh, 2 hypochromic macules on the left thigh, and a small number of fibrous plaques on the right thigh. Abdominal examination found bilateral lumbar tenderness and neurological examination is without peculiarities cranial and thoraco abdominal scan (done after an accidental fall of the left drain) objectified a bilateral cystic pulmonary lesion and a right pneumothorax (Figure 1).

In addition to the chest abnormalities, the scan showed subependymal cerebral nodules (Figure 2) and renal mass on both sides (angiomyolipoma) (Figure 3).

A surgical pleurodesis was proposed, but the patient was recused by the anaesthetist because of the major risk of ventilating pathological lungs. The evolution was marked by the return of the lung to the wall, mTOR inhibitors were prescribed to the patient at her discharge from hospital.

**Discussion**

Lymphangiomymatosis is a rare disease in young women, in period of genital activity, the average age of diagnosis varies between 30 and 45 years [1]. During the course of the Bourneville's tubular sclerosis, the physiopathology implies the mutation of the tumour suppressor genes TSC1 and TSC2. Pulmonary lymphangiomymatosis is often discovered in the course of a pneumothorax. The Suspicion of tuberous bourneville sclerosis requires a complete systematic review in search of other systemic disorders, the diagnosis of BTS is based on clinical, radiological and sometimes genetic criteria (Table 1) [2]. It is the identification of the two genes responsible for the disease which, by making it possible to understand how these tumors were forming, paved the way for treatment medical. A crucial discovery was that proteins encoded by these two genes form a complex that physiologically inhibits the mTOR signaling pathway (for mammalian Target of Rapamycin), which has a role central to the physiological control of proliferation cell phone.
It appeared that when one of these proteins is deficient due to a mutation of TSC1 or TSC2, the excessive activation of this signaling channel mTOR conducts, in tissues where a second somatic mutation, to the tumor proliferation that goes constitute the hamartome. Hence the use of mTOR inhibitors (already used in organ transplantation): sirolimus or rapamycin (Rapamune®) or everolimus (Certican®). The effect of these drugs was first tested in animal models and then in a few patients with large cerebral or renal hamartoma. The results being favourable, clinical trials were conducted in patients with renal manifestations [3], pulmonary [3], and cerebral [4]. The results are impressive and consistent: after 6 months of treatment, the size of the tumors in these various organs is reduced by more than 30% in 75% of cases of patients [5]. In two recent clinical trials reported using everolimus in 117 patients treated for cerebral astrocytoma (84% under the age of 18 years of age) and 118 treated for renal Angiomyolipoma, a reduction of size of more than 50% of the targeted tumours is obtained, at the After one year, in 35 and 42% of patients, respectively [6,7]. At the end of the current follow-up (19-33 months; mean 28 months), the lesions continue to decrease or in any case stabilize. However, these drugs do cause enough often some side effects, including the main are stomatitis and respiratory tract infections [8,9]. Rapamycin has also been tested in topical use. At concentrations ranging from 0.003% to 1% for the treatment of angiofibromas of the face, with results very encouraging both in size and appearance. Other treatments can be offered: recurrent pneumothorax may warrant pleural symphysis, avoiding talcum powder or chemical symphyses which can complicate transplant surgery, in favor of partial pleurectomies by video surgery [10]. The iterative punctures have not proved to be effective, pleurodesis with or without ligation of the thoracic duct may be justified in case of recurrent symptomatic forms. Conservative surgical removal and/or selective embolisation of renal angiomyolipoma and considered in case of haemorrhagic complication or angiomyolipoma measuring more than 4 cm [11]. For the lung damage, although there are mild forms, lymphangioleiomyomatosis most often progresses to chronic respiratory failure within a few years or decades. Hormone therapy has not been shown to be effective in the absence of controlled clinical trials. Lung transplantation is the last therapeutic option, with rare recurrences on transplanted lungs having been reported.

### Conclusion

Pulmonary lymphangiomymatosis most often progresses to chronic respiratory failure within a few years or decades. Hormonal therapy has not been shown to be effective in the absence of controlled clinical trials. Lung transplantation is the last therapeutic resort; rare recurrences of transplanted lungs have been reported.

### References


